Home > ACMD advice on sativex.

Advisory Council on the Misuse of Drugs. [Home Office UK] (2013) ACMD advice on sativex. London: Advisory Council on the Misuse of Drugs. 2 p.

[img] PDF (ACMD advice on sativex) - Published Version
134kB

Letter from the Chair of the ACMD to Jeremy Browne, Minister for Crime Prevention, UK Home Office, re the definition of cannabis based medicine.

In October 2012 the UK Home Office presented to the ACMD a revised definition of cannabis based medicines, such as Sativex, under the Misuse of Drugs Regulations 2001. The ACMD gave detailed consideration to the the options and concludes that the most appropriate definition is:

“A liquid formulation–
(a) containing a botanical extract of Cannabis –
(i) with a concentration of not more than 30 milligrammes of cannabidiol per millilitre, and not more than 30 milligrammes of delta-9-tetrahydrocannabinol per millilitre, and
(ii) where the ratio of cannabidiol to delta-9-tetrahydrocannabinol is between 0.7 and 1.3
(b) which is dispensed through a metered dose pump as a mucosal mouth spray and which was approved for marketing by the Medicines and Healthcare Products Regulatory Agency (MHRA)”


Item Type:Evidence resource
Publication Type:Other
Drug Type:Prescription/Over the counter, Cannabis
Intervention Type:Screening
Source:Home Office UK
Date:February 2013
Pages:2 p.
Publisher:Advisory Council on the Misuse of Drugs
Corporate Creators:Advisory Council on the Misuse of Drugs
Place of Publication:London
EndNote:View
Accession Number:HRB (Electronic Only)
Related URLs:
Subjects:B Substances > Cannabis product (synthetic cannabinoids)
E Concepts in biomedical areas > Substance by legal status > Controlled substance
VA Geographic area > Europe > United Kingdom
E Concepts in biomedical areas > Substance by legal status > Prescription drug (medicine / medication)
B Substances > Cannabis / Marijuana

Repository Staff Only: item control page